Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Group net debt development Net debt higher by CHF -2.7bn compared to previous YE 2021 CHFbn Free Cash Flow CHF 7.1bn vs. 6.0bn in 2021 -18.2 +9.8 Dividends paid -7.7 Taxes Treasury -2.5 Trans. own eq. instr. -0.6 -0.2 M&A & All. trans. 0.0 Curr. Transl. & Other -1.5 -2.7 -20.9 -9.8 Roche Net debt Operating Non-Operating 31 Dec 2021 Free Cash Flow Free Cash Flow Dividends, M&A and Alliance transactions and other Net debt 30 Jun 2022 Intangible Asset Equity M&A Thereof investments in innovation: 2022 -0.3 0.0 0.0 Total -0.3 2021 -0.3 0.0 -1.9 -2.2 65

View entire presentation